Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment marks Jeito’s first